Hyundai Pharmaceutical Co., Ltd. (KRX:004310)
3,650.00
+10.00 (0.27%)
Last updated: Nov 6, 2025, 9:23 AM KST
Hyundai Pharmaceutical Revenue
In the fiscal year ending November 30, 2013, Hyundai Pharmaceutical had annual revenue of 108.14B KRW with 5.75% growth. Hyundai Pharmaceutical had revenue of 25.51B in the quarter ending November 30, 2013, with 5.01% growth.
Revenue
108.14B
Revenue Growth
+5.75%
P/S Ratio
0.93
Revenue / Employee
275.15M
Employees
393
Market Cap
100.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2013 | 108.14B | 5.88B | 5.75% |
| Nov 30, 2012 | 102.25B | -12.02B | -10.52% |
| Nov 30, 2011 | 114.28B | 2.42B | 2.16% |
| Nov 30, 2010 | 111.86B | -11.02B | -8.97% |
| Nov 30, 2009 | 122.88B | 2.36B | 1.96% |
| Nov 30, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |